Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Modified antibody detects HER-2 over-expression in breast cancer
June 2nd, 2005
A modified Trastuzumab antibody has been used for the immunohistochemical detection of HER-2 over-expression in breast cancer. According to recent research published in the British Journal of Cancer, "the immunohistochemical determination of HER-2 to identify patients with advanced breast cancer candidates for Trastuzumab treatment proved neither accurate nor fully reliable, possibly because none of the current reagents detects the specific antigenic site target of Trastuzumab. "To circumvent this problem, we conjugated the NH2 groups of Trastuzumab with biotin, and the compound obtained, designated BiotHER, was added directly to tissue...
Source: Women's Health Weekly (2005-06-02)
|
